Pfizer wins blockbuster Lyrica patent extension to safeguard sales till June

Pfizer, looking to protect billions in Lyrica sales, has been gunning for a 6-month pediatric exclusivity extension for its top drug. And on Tuesday, the FDA came through in favor of the drugmaker.